Submit to Special Issue Submit Abstract to Special Issue Review for Antibiotics Edit a Special Issue

Journal Menu

Journal Browser

► Journal Browser

Special Issue "Antimicrobial Peptides from Natural Sources to Synthetic Optimization"

Print Special Issue Flyer
Special Issue Editors
Special Issue Information
Keywords
Published Papers
Planned Papers

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Antimicrobial Peptides".

Deadline for manuscript submissions: 30 June 2023 | Viewed by 5220

Share This Special Issue

Special Issue Editors

Dr. Javier Eduardo García Castañeda

E-Mail Website
Guest Editor

Departamento de Farmacia, Facultad de Ciencias, Universidad Nacional de Colombia, Bogotá Carrera 45 No 26-85, Building 450, Bogotá 11321, Colombia
Interests: peptide synthesis; antimicrobial and anticancerigenic peptides; glycopeptides; organometallic peptides

Dr. Zuly Jenny Rivera-Monroy

E-Mail Website
Guest Editor

Departamento de Química, Facultad de Ciencias, Universidad Nacional de Colombia, Bogotá Carrera 45 No 26-85, Building 451, Bogotá 11321, Colombia
Interests: peptide synthesis; peptide therapeutic application; peptide analysis by HPLC and MS

Special Issue Information

Dear Colleagues,

Antimicrobial peptides (AMPs) are considered the main resource for the development of new therapeutic alternatives against antimicrobial infections. AMPs have been identified in plants and animals with very diverse primary and secondary structures, which give them physicochemical properties that are fundamental for their antimicrobial activity. It has been pointed out that AMPs have some deficiencies that limit their use as drugs, such as proteolytic susceptibility, easy and rapid elimination from the body, difficulty in crossing membranes, undesirable side effects, etc. Therefore, the identification of promising AMPs is the cornerstone in the development of drugs to mitigate the impact of antimicrobial infections, especially those caused by resistant strains. AMPs that have been identified and/or isolated from natural sources are the starting point for the design and development of new molecules with enhanced antimicrobial activity and in some cases these AMPs have been commercialized, increasing our therapeutic options. The design and optimization of peptide sequences involves different synthetic strategies such as: obtaining short linear sequences, dendrimers, cyclic peptides, dimeric peptides, tetrameric peptides, polymeric peptides, inclusion of non-natural amino acids, D-amino acids, organic molecules of non-peptide origin, etc. These modifications require the simultaneous use of methodologies such as solid phase and solution chemical synthesis, click chemistry, oxidation reactions, recombinant technology, etc. Although significant progress has been made in improving the antimicrobial activity of molecules, it is clear that much remains to be done as there is an urgent need for more therapeutic options to combat antimicrobial infections, which are now considered a global public health problem.

Dr. Javier Eduardo García Castañeda
Dr. Zuly Jenny Rivera-Monroy
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

antimicrobial peptides
mimetic peptides
defensins
antimicrobial proteins
dendrimeric peptides
peptide chemistry synthesis
recombinant peptide synthesis

Published Papers (6 papers)

Download All Papers

Research

Open AccessArticle

D- and N-Methyl Amino Acids for Modulating the Therapeutic Properties of Antimicrobial Peptides and Lipopeptides

Maria Veronica Humpola

Roque Spinelli

Melina Erben

Virginia Perdomo

Georgina Guadalupe Tonarelli

Fernando Albericio

and

Alvaro Sebastian Siano

Antibiotics 2023, 12(5), 821; https://doi.org/10.3390/antibiotics12050821 - 27 Apr 2023

Viewed by 418

Abstract

Here we designed and synthesized analogs of two antimicrobial peptides, namely C10:0-A2, a lipopeptide, and TA4, a cationic α-helical amphipathic peptide, and used non-proteinogenic amino acids to improve their therapeutic properties. The physicochemical properties of these analogs were analyzed, including their retention time, hydrophobicity, and critical micelle concentration, as well as their antimicrobial activity against gram-positive and gram-negative bacteria and yeast. Our results showed that substitution with D- and N-methyl amino acids could be a useful strategy to modulate the therapeutic properties of antimicrobial peptides and lipopeptides, including enhancing stability against enzymatic degradation. The study provides insights into the design and optimization of antimicrobial peptides to achieve improved stability and therapeutic efficacy. TA4(dK), C10:0-A2(6-NMeLys), and C10:0-A2(9-NMeLys) were identified as the most promising molecules for further studies. Full article

(This article belongs to the Special Issue Antimicrobial Peptides from Natural Sources to Synthetic Optimization)

► Show Figures

Figure 1

Open AccessArticle

The Antimicrobial Peptide Octopromycin Suppresses Biofilm Formation and Quorum Sensing in Acinetobacter baumannii

Dinusha Chathurangi Rajapaksha

Shan Lakmal Edirisinghe

Chamilani Nikapitiya

Ilson Whang

and

Mahanama De Zoysa

Antibiotics 2023, 12(3), 623; https://doi.org/10.3390/antibiotics12030623 - 21 Mar 2023

Viewed by 881

Abstract

Acinetobacter baumannii is an opportunistic bacterial pathogen that causes severe infections in immunocompromised individuals. A. baumannii forms biofilm and produces extracellular matrix, which supports bacteria to survive under harsh conditions and be resistant to antibacterial treatments. In the present study, we investigated the biofilm and quorum-sensing inhibitory effects of antimicrobial peptide, octopromycin in A. baumannii. Field emission-scanning electron microscopy results clearly showed significantly reduced biofilm mass and caused a collapse in biofilm architecture at the minimum inhibitory concentration (50 µg/mL) and minimum bactericidal concentration (200 µg/mL) of octopromycin. Antibiotic-resistant persister cells of A. baumannii were successfully killed by octopromycin treatment, and it inhibited violacein production in Chromobacterium violaceum in a concentration-dependent manner. Octopromycin also inhibited alginate production, surface movements (swarming and swimming), and twitching motility of A. baumannnii, confirming its anti-quorum-sensing activity. Multiple metabolic pathways, two-component regulation systems, quorum-sensing, and antibiotic synthesis-related pathways in A. baumannii biofilms were strongly affected by octopromycin treatment. The collective findings indicate that the antibacterial peptide octopromycin may control A. baumannii biofilms through multi-target interactions. Octopromycin could be a desirable therapeutic option for the prevention and control of A. baumannii infections. Full article

(This article belongs to the Special Issue Antimicrobial Peptides from Natural Sources to Synthetic Optimization)

► Show Figures

Figure 1

Open AccessArticle

Comparative Evaluation of Existing and Rationally Designed Novel Antimicrobial Peptides for Treatment of Skin and Soft Tissue Infections

and

Antibiotics 2023, 12(3), 551; https://doi.org/10.3390/antibiotics12030551 - 10 Mar 2023

Viewed by 857

Abstract

Skin and soft tissue infections (SSTIs) and acne are among the most common skin conditions in primary care. SSTIs caused by ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter sp.) can range in severity, and treating them is becoming increasingly challenging due to the growing number of antibiotic-resistant pathogens. There is also a rise in antibiotic-resistant strains of Cutibacterium acne, which plays a role in the development of acne. Antimicrobial peptides (AMPs) are considered to be a promising solution to the challenges posed by antibiotic resistance. In this study, six new AMPs were rationally designed and compared to five existing peptides. The MIC values against E. coli, P. aeruginosa, K. pneumoniae, E. faecium, S. aureus, and C. acnes were determined, and the peptides were evaluated for cytotoxicity using Balb/c 3T3 cells and dermal fibroblasts, as well as for hemolytic activity. The interaction with bacterial membranes and the effect on TNF-α and IL-10 secretion were also evaluated for selected peptides. Of the tested peptides, RP556 showed high broad-spectrum antibacterial activity without inducing cytotoxicity or hemolysis, and it stimulated the production of IL-10 in LPS-stimulated peripheral blood mononuclear cells. Four of the novel AMPs showed pronounced specificity against C. acnes, with MIC values (0.3–0.5 μg/mL) below the concentrations that were cytotoxic or hemolytic. Full article

(This article belongs to the Special Issue Antimicrobial Peptides from Natural Sources to Synthetic Optimization)

► Show Figures

Figure 1

Open AccessArticle

In Vitro Antifungal Activity of Chimeric Peptides Derived from Bovine Lactoferricin and Buforin II against Cryptococcus neoformans var. grubii

Silvia Katherine Carvajal

Yerly Vargas-Casanova

Héctor Manuel Pineda-Castañeda

Javier Eduardo García-Castañeda

Zuly Jenny Rivera-Monroy

and

Claudia Marcela Parra-Giraldo

Antibiotics 2022, 11(12), 1819; https://doi.org/10.3390/antibiotics11121819 - 15 Dec 2022

Viewed by 766

Abstract

Cryptococcosis is associated with high rates of morbidity and mortality. The limited number of antifungal agents, their toxicity, and the difficulty of these molecules in crossing the blood–brain barrier have made the exploration of new therapeutic candidates against Cryptococcus neoformans a priority task. To optimize the antimicrobial functionality and improve the physicochemical properties of AMPs, chemical strategies include combinations of peptide fragments into one. This study aimed to evaluate the binding of the minimum activity motif of bovine lactoferricin (LfcinB) and buforin II (BFII) against C. neoformans var. grubii. The antifungal activity against these chimeras was evaluated against (i) the reference strain H99, (ii) three Colombian clinical strains, and (iii) eleven mutant strains, with the aim of evaluating the possible antifungal target. We found high activity against these strains, with a MIC between 6.25 and 12.5 µg/mL. Studies were carried out to evaluate the effect of the combination of fluconazole treatments, finding a synergistic effect. Finally, when fibroblast cells were treated with 12.5 µg/mL of the chimeras, a viability of more than 65% was found. The results obtained in this study identify these chimeras as potential antifungal molecules for future therapeutic applications against cryptococcosis. Full article

(This article belongs to the Special Issue Antimicrobial Peptides from Natural Sources to Synthetic Optimization)

► Show Figures

Figure 1

Open AccessArticle

Chimeric Peptides Derived from Bovine Lactoferricin and Buforin II: Antifungal Activity against Reference Strains and Clinical Isolates of Candida spp.

Katherine Aguirre-Guataqui

Mateo Márquez-Torres

Héctor Manuel Pineda-Castañeda

Yerly Vargas-Casanova

Andrés Ceballos-Garzon

Zuly Jenny Rivera-Monroy

Javier Eduardo García-Castañeda

and

Claudia Marcela Parra-Giraldo

Antibiotics 2022, 11(11), 1561; https://doi.org/10.3390/antibiotics11111561 - 05 Nov 2022

Cited by 3 | Viewed by 976

Abstract

Antimicrobial peptides (AMPs) are considered to be a valuable source for the identification and/or design of promising candidates for the development of antifungal treatments, since they have advantages such as lower tendency to induce resistance, ease of production, and high purity and safety. Bovine lactoferricin (LfcinB) and Buforin II (BFII) are AMPs to which great antimicrobial potential has been attributed. The minimum motives with antimicrobial activity derived from LfcinB and BFII are RRWQWR and RLLR, respectively. Nine chimeras containing the minimum motives of both peptides were synthesized and their antifungal activity against fluconazole (FLC)-sensitive and resistant C. albicans, C. glabrata, and C. auris strains was evaluated. The results showed that peptides C9: (RRWQWR)₂K-Ahx-RLLRRRLLR and C6: KKWQWK-Ahx-RLLRRLLR exhibited the greatest antifungal activity against two strains of C. albicans, a FLC-sensitive reference strain and a FLC-resistant clinical isolate; no medically significant results were observed with the other chimeras evaluated (MIC ~200 μg/mL). The chimera C6 was also active against sensitive and resistant strains of C. glabrata and C. auris. The combination of branched polyvalent chimeras together with FLC showed a synergistic effect against C. albicans. In addition to exhibiting antifungal activity against reference strains and clinical isolates of Candida spp., they also showed antibacterial activity against both Gram-positive and Gram-negative bacteria, suggesting that these chimeras exhibit a broad antimicrobial spectrum and can be considered to be promising molecules for therapeutic applications. Full article

(This article belongs to the Special Issue Antimicrobial Peptides from Natural Sources to Synthetic Optimization)

► Show Figures

Figure 1

Open AccessArticle

Antifungal Activity of Avocado Seed Recombinant GASA/Snakin PaSn

Marco Antonio Hernández-Martínez

Luis María Suárez-Rodríguez

Joel Edmundo López-Meza

Alejandra Ochoa-Zarzosa

Rafael Salgado-Garciglia

Silvia Patricia Fernández-Pavia

and

Rodolfo López-Gómez

Antibiotics 2022, 11(11), 1558; https://doi.org/10.3390/antibiotics11111558 - 05 Nov 2022

Cited by 1 | Viewed by 852

Abstract

The avocado fruit (Persea americana) has become a significant fruit in the human diet for its nutritional properties. However, the seed is a source of bioactive molecules and has been poorly utilized. Previously, we reported that the PaSn gene is expressed in the avocado seeds, a cysteine-rich antimicrobial peptide (GASA/Snakin), and demonstrated its antibacterial activity. In this work, we report the recombinant production of PaSn in the Escherichia coli system and evaluate its antifungal activity against plant and human pathogen fungi. The recombinant peptide showed antifungal activity at 200 μg/mL against phytopathogens Colletotrichum gloeosporioides and Fusarium oxysporum and human pathogens Candida albicans and C. glabrata. Our results demonstrate the usefulness of a prokaryotic expression system for avocado antimicrobial peptide production. In conclusion, the snakin PaSn could be helpful in the control of postharvest avocado and other fruits’ fungal diseases and human fungal pathogens. Full article

(This article belongs to the Special Issue Antimicrobial Peptides from Natural Sources to Synthetic Optimization)

► Show Figures

Figure 1

Planned Papers

The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.

1. Chimeric peptides derived from Bovine Lactoferricin and Buforin II: antifungal activity against reference strains and clinical isolates of Candida spp.

Katherine Aguirre-Guataqui¹, Mateo Márquez-Torres², Héctor Pineda-Castañeda³, Andrés Ceballos-Garzon¹, Yerly Vargas-Casanova¹, Zuly Rivera-Monroy², Javier García-Castañeda² and Claudia M Parra-Giraldo¹*

2. In vitro antifungal activity of chimeric peptides derived from Bovine Lactoferricin and Buforin II against Cryptococcus neoformans var. grubii

Silvia Katherine Carvajal ¹, Yerly Vargas-Casanova ¹, Héctor Manuel Pineda-Castañeda ², Javier Eduardo García-Castañeda ³, Zuly Jenny Rivera-Monroy ², Claudia Marcela Parra Giraldo ^1, *

Journal Menu

Journal Browser

Special Issue "Antimicrobial Peptides from Natural Sources to Synthetic Optimization"

Share This Special Issue

Special Issue Editors

Special Issue Information

Keywords

Published Papers (6 papers)

Research

Planned Papers

Further Information

Guidelines

MDPI Initiatives

Follow MDPI